MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

MDS Rare Movement Disorders Study Group Global Genetic Testing Survey: exploring the unmet needs

R. Walker, H. Jinnah, M. Rodriguez Violante, C. Gonzalez, E. Gatto (New York, NY, USA)

Meeting: 2019 International Congress

Abstract Number: 549

Keywords: Ataxia: Genetics, Chorea (also see specific diagnoses, Huntingtons disease, etc): Genetics, Dystonia: Genetics

Session Information

Date: Monday, September 23, 2019

Session Title: Rare Genetic and Metabolic Diseases

Session Time: 1:45pm-3:15pm

Location: Les Muses Terrace, Level 3

Objective: To better understand access to genetic testing at the international level.

Background: One of the objectives of the Rare Diseases Study Group (RDSG) of the International Parkinson Disease and Movement Disorder Society (IPMDS) is to improve the diagnosis and management of rare movement disorders

Method: We conducted an observational, cross-sectional study. Members of the RDSG designed a 21-question on-line survey, which was electronically mailed to all 7815 members affiliated with IPMDS.

Results: 1269 surveys (=16% response rate; 93.0% fully completed) were received from 109 countries. 53.8% of respondents reported > 10 years in clinical practice. 45.4% of respondents identified themselves as movement disorders specialists or consultants. Almost 90% of respondents were primarily involved in clinical care. Patients were found to have 10 times less access to a movement disorder specialist or a pediatric neurologist than a general physician and 25-33 times less access to a genetic specialist. Access to specific tests (whole exome sequencing and genetic panels for Parkinsonism, dystonia, ataxia and other disorders) were limited and considered unaffordable for 35-40% of respondents. Genetic tests for ataxias and Huntington’s disease were the most commonly available tests at the respondents’ home institutions (available to 40%-43%, respectively). For other tests [HD-like, metabolic disorders, etc.] average availability was 26%. Most genetic tests were provided by universities and academic centers (52.8%), followed by private institutions (40.8%), and government or public institutions (36%) with some overlap in resources.  The cost of testing was reported to be covered by patients (65.4%), government or public health insurance (55.8%), and private health insurance companies (33.7%). A national network for genetic testing was reported by only 36.7%;   >60% of respondents answered that they were not aware of an international agreement for genetic testing.

Conclusion: Despite limitations, this survey is an initiative to highlight the major global challenges and disparities, not only for the availability of genetic testing, but also for access to movement disorders specialists and genetic clinics for movement disorders.

To cite this abstract in AMA style:

R. Walker, H. Jinnah, M. Rodriguez Violante, C. Gonzalez, E. Gatto. MDS Rare Movement Disorders Study Group Global Genetic Testing Survey: exploring the unmet needs [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/mds-rare-movement-disorders-study-group-global-genetic-testing-survey-exploring-the-unmet-needs/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/mds-rare-movement-disorders-study-group-global-genetic-testing-survey-exploring-the-unmet-needs/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley